Stock Chart

KLRS

$2.70 -5.26%
Score: 37.9 AVOID NEW MONEY
Pro
Screener
Vol: 3.29x (vs SPY: 3.3x | vs QQQ: 3.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
No qualifying chart pattern in the trailing 60 sessions — we only flag setups that pass our quality gate.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About KLRS - Kalaris Therapeutics, Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Key Statistics

Market Cap $69M

This KLRS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track KLRS's price movements with trendlines, gamma walls, and key support/resistance levels.